Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.
about
Neuromodulatory effect of propentofylline on rat brain under acute and long-term hypoperfusionAdenosine receptors as drug targets--what are the challenges?Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro.Adenosine and neurotrauma: therapeutic perspectives.Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction.Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning.Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protectionPlasticity of purine release during cerebral ischemia: clinical implications?Adenosine A3 receptor stimulation and cerebral ischemiaAdenosine receptor ligands: differences with acute versus chronic treatment.Adenosine: a prototherapeutic concept in neurodegeneration.Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist.Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist.Adenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea.Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist.Ischemic tolerance as an active and intrinsic neuroprotective mechanism.How does adenosine control neuronal dysfunction and neurodegeneration?Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders.Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling.Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A1 receptors.Block by N6-L-phenylisopropyl-adenosine of the electrophysiological and morphological correlates of hippocampal ischaemic injury in the gerbil.Pharmacological manipulations of ATP-dependent potassium channels and adenosine A1 receptors do not impact hippocampal ischemic preconditioning in vivo: evidence in a highly quantitative gerbil model.Biochemical and Pharmacological Role of A1 Adenosine Receptors and Their Modulation as Novel Therapeutic Strategy.Adenosine A2AReceptors and NeuroprotectionNeuroprotection by A2A receptor antagonists
P2860
Q28363819-08E870FF-8071-4334-BAF9-E3A908E5081AQ29346491-BD90EFCD-EF8F-49CD-8245-F4CF160F5E04Q31108561-4B706136-7409-491F-842F-10A99DEF84D0Q34230282-158CF963-92D8-4399-899D-343E07367868Q34292324-B7DD577D-411F-44E6-B285-758ED138663CQ34357041-2806DD51-A336-47E0-8066-0A298D5A775BQ34999682-C4A0D223-89C7-4630-B924-3B99DD511773Q35644634-BFD0A766-7EF9-4EE2-AFDB-361F2E04D516Q36185246-DDC9A6D3-628F-41A5-9E87-44B6AA05966BQ36200374-CD45006C-E880-4AA8-A2D0-ABCFC1B29E2AQ36219758-772BDF89-E8CC-4A4D-BAD0-B6F855A97FF0Q36225561-0C8690B0-3A81-459D-9684-B4E55C6BAE50Q36253717-D3614197-A844-43BE-9AD2-E921C1FB8D37Q36768399-F863FE92-1689-42C3-86BB-A68A75D4E3DDQ36785534-20158192-216C-4883-8F69-33E7DCA8C517Q37268106-CA03A570-5658-4A07-ACB7-426BDE727DADQ38882782-57EF828B-CA63-409D-8885-6D8C8E38304FQ41643075-44458460-7846-420C-8F98-F9AB6D072EC0Q41767515-95A808F8-A940-4C35-B492-558F790F365CQ41874151-D578555E-36BA-4F8E-BCCB-D95E69E9768CQ42704130-C68890D9-ABA6-4599-834A-5CC68AB975FBQ44885318-10E2E1DB-854E-4496-A4D8-79B3551397FAQ48732639-65C5DE9D-6F92-442F-B167-9540514CFDB6Q56700736-0EAEE274-3AAA-42FE-9ACB-C41B2CA6B94EQ58852531-EEE3D8B0-2CEA-4048-85FB-E6F4D0BE996E
P2860
Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Chronic administration of sele ...... tagonist in cerebral ischemia.
@en
type
label
Chronic administration of sele ...... tagonist in cerebral ischemia.
@en
prefLabel
Chronic administration of sele ...... tagonist in cerebral ischemia.
@en
P2093
P2860
P1476
Chronic administration of sele ...... tagonist in cerebral ischemia.
@en
P2093
P2860
P304
P356
10.1016/0014-2999(94)90241-0
P407
P577
1994-04-01T00:00:00Z